Pertuzumab

Red

Brand Name(s):Perjeta

Indication:Metastatic Breast Cancer
Neoadjuvant Treatment of Breast Cancer

Rationale:1,2,3

Considered:Jan-17

Review Date:Jan-22

Comments:
NICE TA 424
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Dec-16